Know Cancer

forgot password

Whole Human Genome Oligo Microarray Analysis of the Peripheral Blood Mononuclear Cells of Patients With Ankylosing Spondylitis During Infliximab Treatment Compared to Healthy Controls

Phase 4
18 Years
70 Years
Not Enrolling
Spondylitis, Ankylosing

Thank you

Trial Information

Whole Human Genome Oligo Microarray Analysis of the Peripheral Blood Mononuclear Cells of Patients With Ankylosing Spondylitis During Infliximab Treatment Compared to Healthy Controls

Inclusion Criteria:

- Diagnosis of ankylosing spondylitis proven by appropriate diagnostic methods
(according to New York criteria).

- Refractory disease defined by failure of at least 2 non-steroidal anti-inflammatory
drugs (NSAIDs) during a 3-month period and failure of sulfasalazine in subjects with
associated peripheral arthritis.

- Active disease defined by:

- sustained bath ankylosing spondylitis disease activity index (BASDAI) of at
least 40 on a 0-100 scale and

- expert opinion based on clinical features.

- Age between 18 and 70 years.

- Subjects using NSAIDs and/or sulfasalazine must have been on a stable dose for at
least 4 weeks prior to study initiation, and may continue medication during the
treatment period, but the dose must not be increased above the baseline.

- Subjects must be capable to demonstrate their willingness to participate in the study
and comply with its procedures by signing a written informed consent.

- Men and women of childbearing potential (includes women who are less than 1 year
postmenopausal and women who become sexually active) must be using an acceptable
method of birth control (eg, hormonal contraceptive, medically prescribed
intrauterine device (IUD), condom in combination with spermicide) or be surgically
sterilized (eg, hysterectomy or tubal ligation).

- Subjects must understand and be able to adhere to the dosing and visit schedules.

Exclusion Criteria:

- Subject with moderate or severe heart failure (New York Heart Association (NYHA)
class III/IV).

- Remicade must not be given to subjects with a history of hypersensitivity to
infliximab, to other murine proteins, or to any of the excipients.

- Subjects with pre-existing or recent onset of central nervous system demyelinating

- Age <18 or >70 years.

- Pregnant women, nursing mothers.

- Subjects who are incapacitated, largely or wholly bedridden or confined to a
wheelchair, and who have little or no ability for self-care.

- Subjects who have any current systemic inflammatory condition with signs and symptoms
that might confound the evaluations of benefit from infliximab therapy.

- Prior administration of infliximab or any other therapeutic agent targeted at
reducing tumor necrosis factor (TNF) (eg, Etanercept, pentoxifylline, thalidomide or
anti-CD4+ antibody).

- Current treatment with systemic corticosteroid.

- Treatment with any investigational drug within the previous 3 months.

- History of known allergies to murine proteins.

- Subjects having active or inactive tuberculosis (TB). All subjects must be evaluated
for both active and inactive ('latent') TB. This evaluation should include a
detailed medical history with personal history of TB or possible previous contact
with TB and previous and/or current immunosuppressive therapy. Appropriate screening
tests (ie, tuberculin skin test and chest x-ray) should be performed in all subjects.

- Serious infection, such as sepsis, abscesses, hepatitis, pneumonia, pyelonephritis in
the previous 3 months. Less serious infections in the previous 3 months, such as
acute respiratory tract infection (colds) or uncomplicated urinary tract infection
need not be considered exclusions at the discretion of the treating physician.

- History of opportunistic infections such as herpes zoster within 2 months of study
initiation. Evidence of active cytomegalovirus (CMV), active pneumocystis carinii,
drug resistant atypical mycobacterium, etc.

- Documented human immunodeficiency virus (HIV) infection.

- Current signs or symptoms of severe, progressive or uncontrolled renal, hepatic,
hematologic, endocrine, pulmonary, cardiac, neurological, or cerebral disease.

- Any currently known malignancy or pre-malignant lesions or any history of malignancy
within the past 5 years (except non-melanoma skin cancer and surgically cured
cervical cancer).

- Subjects with alcoholism, alcoholic liver disease, or other chronic liver disease.

Type of Study:


Study Design:

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Number of Genes Which Were Differentially Expressed

Outcome Description:

Differentially expressed genes were described as those which were at least 1.5 times up- or down-regulated and statistically different at a significance level of 0.05 using a paired t-test comparing 10 ankylosing spondylitis (AS) participants during tumor necrosis factor (TNF) alpha treatment (Remicade) with 10 matched controls. Control samples were previously obtained and not specifically collected for this study.

Outcome Time Frame:

14 weeks

Safety Issue:



Hungary: National Institute of Pharmacy

Study ID:




Start Date:

October 2004

Completion Date:

February 2007

Related Keywords:

  • Spondylitis, Ankylosing
  • Spondylitis
  • Spondylitis, Ankylosing